Karyopharm Therapeutics Inc. · NASDAQ:KPTI
Karyopharm Therapeutics — Q2 2026 Earnings Presentation
40 slides from Karyopharm Therapeutics's earnings presentation, Aug 13, 2026
Slide 1: Second Quarter 2026 Financial Results & Business Update
Second Quarter 2026 Financial Results & Business Update August 13, 2026
Slide 2: On Today's Call
On Today’s Call • Welcome Brendan Strong, SVP, Investor Relations • Overview Richard Paulson, President and Chief Executive Officer • Myelofibrosis Update Dr. Reshma Rangwala, Chief Medical Officer and Head of Research • Myelofibrosis Opportunity and Commercial Highlights Sohanya Cheng, Chief Commer
Slide 3: Forward-looking Statements and Other Important Information
Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm’s guidance on its 2026 total revenue, 2026 U
Slide 4: Overview
OVERVIEW Richard Paulson President and Chief Executive Officer ©2026 KARYOPHARM THERAPEUTICS INC.
Slide 5: SENTRY Data in the Scientific Spotlight Generating Strong Interest
SENTRY Data in the Scientific Spotlight Generating Strong Interest • Late-Breaking Oral Presentation at ASCO • Manuscript Published in JCO • Late-Breaking Oral Presentation at EHA • One of six best abstracts ©2026 KARYOPHARM THERAPEUTICS INC. 5
Slide 6: sNDA Submission Planned for August
On Track to Submit sNDA in August and Potentially be First Combination Therapy Approved in Myelofibrosis SVR35 Appears to Qualify as a Reasonably Likely Surrogate Endpoint (RLSE) sNDA Submission Plan to use Long-Term Overall Planned for August Survival from SENTRY to Confirm Clinical Benefit Priorit
Slide 7: Focused to Deliver on Transformative Opportunity in Myelofibrosis
Focused to Deliver on Transformative Opportunity in Myelofibrosis Focus on Hematology with Transformative Myelofibrosis Opportunity and Profitable Multiple Myeloma Foundation U.S. MYELOFIBROSIS MARKET Advance sNDA; Compendia; Global Regulatory Submissions; Consistency in Data, Long Term Follow up of
Slide 8: Multiple Value Generating Inflection Points over the next Six Months
Multiple Value Generating Inflection Points over the next Six Months Potential Inclusion Potential FDA Potential sNDA in Treatment sNDA Submission Approval and Acceptance and Guidelines and Planned in August Launch as Early as Priority Review Compendia in 2H’26 1Q’27 Selinexor has not been approved
Slide 9: Myelofibrosis Update
MYELOFIBROSIS UPDATE Reshma Rangwala, MD, PhD Chief Medical Officer and Head of Research ©2026 KARYOPHARM THERAPEUTICS INC.
Slide 10: XPO1 Inhibition is a Multifaceted Approach to Inhibiting the Drivers of Myelofibrosis
XPO1 Inhibition is a Multifaceted Approach to Inhibiting the Drivers of Myelofibrosis1-9 SEL ↓ Clonal cell division ↓ Splenomegaly XPO-1 Inflammatory c-myc cytokine / chemokine ↓ Variant Allele Frequency c-myc (VAF) Oncogene XPO-1 IκBα Oncogene mRNA ↓ NFκB activity ↓ Cytopenias, fibrosis, constituti
Slide 11: The SENTRY Results Matter in Myelofibrosis Given the Limited Treatment Options and Poor Prognosis
The SENTRY Results Matter in Myelofibrosis Given the Limited Treatment Options and Poor Prognosis Opportunity to Improve Outcomes Four Hallmarks of Myelofibrosis Only ~30% patients achieving Enlarged SVR351 Spleen5 No new class of therapies beyond JAK inhibitors in over 15 years Abnormal Blood Const
Slide 12: Paradigm Shifting Profile with Selinexor plus Ruxolitinib in Myelofibrosis
Paradigm Shifting Profile with Selinexor plus Ruxolitinib in Myelofibrosis Spleen Volume Reduction ≥ 35% (SVR35) Appears to be a Reasonably Likely Surrogate Endpoint (RLSE) Enabling sNDA Submission under Accelerated Approval Pathway Planned sNDA Filing for Post-Hoc Landmark Accelerated Approval Rapi
Slide 13: Significantly Higher SVR35 at Week 24 with Selinexor plus Ruxolitinib versus Ruxolitinib Alone
Significantly Higher SVR35 at Week 24 with Selinexor plus Ruxolitinib versus Ruxolitinib Alone 70 Difference: 21.8% 49.8% 60 Change from baseline in spleen volume (OR 2.58; 95% CI: 1.60, 4.17) 50 60 One-sided P < 0.0001 40 30 SVR35 at Week 24, % 50 28.0% 20 10 (Week 24), % 40 0 −10 30 −20 −30 −40 SV
Slide 14: Rapid, Deep, and Sustained Spleen Volume Reduction with Selinexor plus Ruxolitinib versus Ruxolitinib Alone
Rapid, Deep, and Sustained Spleen Volume Reduction with Selinexor plus Ruxolitinib versus Ruxolitinib Alone Percent change from baseline in spleen volume over time SVR35 rates over time 10 Percent change from baseline in spleen volume over time, mean Selinexor + Placebo + 0 ruxolitinib ruxolitinib S
Slide 15: Consistent SVR35 Benefit Observed Across Prespecified Subgroups
Consistent SVR35 Benefit Observed Across Prespecified Subgroups Favors placebo + ruxolitinib Favors selinexor + ruxolitinib Overall (n = 353) < 65 (n = 146) Age ≥ 65 (n = 207) Male (n = 203) Sex Female (n = 150) White (n = 238) Race Not white (n = 43) North America (n = 75) Geographic region Europe
Slide 16: Selinexor Maintained Spleen Responses Despite Reduced Ruxolitinib Dosing
Selinexor Maintained Spleen Responses Despite Reduced Ruxolitinib Dosing 100.0 80.0 SVR35 at Week 24, % 52.7% 55.3% 60.0 50.0% (26/47) (49/93) (21/42) 40.4% (21/52) 35.1% 40.0 33.3% (13/37) (13/39) 21.9% (7/32) 20.0 0.0% (0/8) 0.0 0 to <15 mg/day 15 to <25 mg/day 25 to <35 mg/day ≥35 mg/day Average
Slide 17: Meaningful Overall Survival with Selinexor Plus Ruxolitinib versus Ruxolitinib Alone
Meaningful Overall Survival with Selinexor Plus Ruxolitinib versus Ruxolitinib Alone 1.00 Selinexor Placebo + + ruxolitinib ruxolitinib Probability of survival Deaths (N = 235) (N = 118) 0.75 Primary cause of death, n (%) Disease progression 3 (1.3) 3 (2.5) Adverse event 3 (1.3) 5 (4.2) Other/Unknow
Slide 18: SVR35 at Week 24 Predicted Overall Survival Irrespective of Treatment
SVR35 at Week 24 Predicted Overall Survival Irrespective of Treatment Landmark analysis at Week 24* 1.00 Probability of survival 0.75 0.50 0.25 98% of SVR35 responders vs 88% of nonresponders were alive at Week 72 + Censored 0.00 0 3 6 9 12 15 18 Time beyond Week 24, months Number at risk SVR35 at W
Slide 19: SENTRY Phase 1 Suggests SVR35 Predicts Overall Survival
SENTRY Phase 1 Suggests SVR35 Predicts Overall Survival 1.00 • In the Phase 1 study, of Probability of overall survival the 15 patients that achieved SVR35 at Week 24, only 1 (6.7%) 0.75 patient died • Of the 9 remaining 0.50 non-responders, 4 (44%) had died 0.25 HR 0.13 + Censored (95% CI 0.02-1.20
Slide 20: SVR35-OS Prediction Observed in SENTRY Builds On Body of Evidence From Ph 3 Trials
SVR35-OS Prediction Observed in SENTRY Builds On Body of Evidence From Ph 3 Trials, Establishing SVR35 as a Reasonably Likely Surrogate Endpoint Internal Analyses. Methods: Plot shows difference in SVR35 rates between treatment arms on the x-axis and the log(HR) for OS on the y-axis. Each point repr
Slide 21: Higher Rates of Driver Gene VAF Reduction ≥ 20% with Selinexor plus Ruxolitinib
Higher Rates of Driver Gene VAF Reduction ≥ 20% with Selinexor plus Ruxolitinib versus Ruxolitinib Alone as Early as Week 24 VAF reduction ≥ 20% at Week 24 35 32.0% Patients with VAF reduction ≥20%, % 30 Association with SVR35 25 23.9% VAF reduction ≥20% was associated with 20 higher likelihood of a
Slide 22: Planned sNDA Submission in August; Strong Scientific Foundation & High Unmet Need
Strong Scientific Foundation & High Unmet Need Supporting Planned Submission Rapid, Near-Doubling and Sustained SVR35 Rates Compared to Ruxolitinib Planned Established Body of Evidence Linking SVR35 with Overall Survival sNDA Submission in August; Promising Signal of Overall Survival Compared to Rux
Slide 23: SENTRY-2 Phase 2 Trial Evaluating Selinexor As Monotherapy in JAKi-Naïve MF Patients
SENTRY-2 (XPORT-MF-044*) Phase 2 Trial Evaluating Selinexor As Monotherapy in JAKi-Naïve MF Patients with Lower Platelet Counts Primary Endpoint Selinexor 60 mg QW • SVR35 at week 24 JAKi-naïve Patients with Myelofibrosis (n=29) Key Secondary Endpoints (n=58) Enrollment Completed • Abs-TSS at week 2
Slide 24: Myelofibrosis Commercialization Readiness
MYELOFIBROSIS COMMERCIALIZATION READINESS Sohanya Cheng Chief Commercial Officer and Head of Business Development ©2026 KARYOPHARM THERAPEUTICS INC.
Slide 25: Established Commercial and Medical Affairs Leadership to Support Potential Myelofibrosis Launch
Established Commercial and Medical Affairs Leadership to Support Potential Myelofibrosis Launch Amama Sadiq MD, MPH SVP, Global Medical & Scientific Affairs Scientific & Medical Affairs Richard Paulson President and CEO Tim Suchanek SVP, National Sales Existing Sales Capabilities to Support Commerci
Slide 26: A Breakout Quarter for SENTRY: Top-tier Recognition Across Leading Global Oncology Platforms
A Breakout Quarter for SENTRY: Top-tier Recognition Across Leading Global Oncology Platforms Advancing SENTRY through scientific leadership, peer-reviewed publication and global dissemination EHA 2026: Selected as a Top 6 Abstract, ASCO 2026: Late-Breaking JCO: Simultaneous recognizing SENTRY as one
Slide 27: Positioning for Targeted Launch with Commercial Organization Covering 100% of Key Accounts
Positioning for Targeted Launch with Commercial Organization Covering 100% of Key Accounts Academic Community >70% of patients treated at Top 50 academic institutions1 Majority of patients U.S. treated in Myelofibrosis five large Community Majority of the 30% Patients Treated by Setting 70% Networks
Slide 28: In a Multi-Billion-Dollar U.S. Market, Selinexor plus Ruxolitinib Could Deliver Up To ~$1B
In a Multi-Billion-Dollar U.S. Market, Selinexor plus Ruxolitinib Combination Could Deliver Up To ~$1B Annually1 in Net Sales at Peak Global Market Prevalence Newly Diagnosed Patients in the U.S. Annually INCIDENCE ✓ ~ 20,000 living with MF in the U.S.2 ✓ ~17,000 living with MF in the EU2 1L JAKi Na
Slide 29: Multiple Myeloma Second Quarter 2026 Highlights
MULTIPLE MYELOMA SECOND QUARTER 2026 HIGHLIGHTS ©2026 KARYOPHARM THERAPEUTICS INC.
Slide 30: Driving Profitable Growth in Multiple Myeloma: Q2 2026 Commercial Highlights
Driving Profitable Growth in Multiple Myeloma Q2 2026 Commercial Highlights Net Product Revenue • U.S. XPOVIO net product revenue was $30.8 million for Q2’26 compared to $29.7 million for Q2’25. $30.8M • Demand for XPOVIO was relatively $29.7M consistent in Q2’26 compared to Q2’25 amidst an increasi
Slide 31: Our Primary Positioning in 2-4L Post-Anti-CD38 in the Community
Our Primary Positioning in 2-4L Post-Anti-CD38 in the Community Supplemented with Expanding Use Pre- and Post T-cell Therapies Lines of Therapy 2L-4L 5L+ 1 Post Dara Unmet Need • Class switch option XVd and NCCN immediately after anti-CD38 Post-Anti-CD38 Therapy listings • Combinability (XPd, XKd, •
Slide 32: Financial Highlights
FINANCIAL HIGHLIGHTS Lori Macomber, CPA Chief Financial Officer and Treasurer ©2026 KARYOPHARM THERAPEUTICS INC.
Slide 33: 2Q 2026 Financial Results and 2026 Guidance
2Q 2026 Financial Results and 2026 Guidance 2Q 2Q Statements of Operations ($ millions) 2026 2025 2026 Financial Guidance Total Revenue $33.4 $37.9 • Total Revenue of $130-$150 million XPOVIO Net Product Revenue 30.8 29.7 License and Other Revenue 2.7 8.2 • U.S. XPOVIO Net Product Revenue of $115-$1
Slide 34: Closing Remarks
CLOSING REMARKS Richard Paulson President and Chief Executive Officer ©2026 KARYOPHARM THERAPEUTICS INC.
Slide 35: Compelling Opportunity in Myelofibrosis
Focused to Deliver on Transformative Opportunity in Myelofibrosis Compelling Experienced Regulatory Path Opportunity in Hematology Forward Myelofibrosis Organization ©2026 KARYOPHARM THERAPEUTICS INC. 35
Slide 36: Appendix
APPENDIX ©2026 KARYOPHARM THERAPEUTICS INC.
Slide 37: Commercial Portfolio and Clinical Pipeline
Commercial Portfolio and Clinical Pipeline Indication Early Stage Mid Stage Late Stage Commercial Multiple myeloma (penta-refractory) w/dexamethasone Multiple myeloma (2L+) w/bortezomib + dexamethasone Myelofibrosis (JAKi naïve) SELINEXOR Endometrial cancer (TP53 WT) Multiple myeloma (2L+ post-anti-
Slide 38: Manageable Safety and Tolerability Profile – Phase 3 SENTRY Results
Manageable Safety and Tolerability Profile – Phase 3 SENTRY Results Selinexor + Placebo + Ruxolitinib Ruxolitinib (N = 234) (N = 116) Safety and tolerability is consistent All Grade TEAEs1 n (%) n (%) with the known profile of selinexor Thrombocytopenia 139 (59.4) 50 (43.1) and ruxolitinib individua
Slide 39: Phase 3 SENTRY Trial Designed to Evaluate Long-Term Outcomes
Phase 3 SENTRY Trial Designed to Evaluate Long-Term Outcomes: SENTRY Does Not Permit Patient Crossover and Trial Remains Blinded Ruxolitiniba BID + Selinexor 60 mg QW Primary Endpoints JAKi-naïve Patients (tested sequentially) with Myelofibrosis (28-day cycle) R SVR35 week 24c (N=353) 2:1 + Ruxoliti
Slide 40: Phase 3 Global Study (XPORT-MM-031/EMN29) Evaluating SPd in Previously Treated Multiple Myeloma
Phase 3 Global Study (XPORT-MM-031/ EMN291)* Evaluating SPd in Patients with Previously Treated Multiple Myeloma Enrollment Complete (n=117)2 SPd (n ~60) SEL: 40 mg3 QW PO D1, 8, 15 and 22 Patients with POM: 4 mg QD PO (D1-21) Pomalidomide-naïve DEX: 40 mg PO D1, 8, 15 and 22 RRMM 28-day cycle Prima
Karyopharm Therapeutics — Q2 2026 Earnings Presentation on 6ix